These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21206344)

  • 21. Stress in women: metabolic syndrome and polycystic ovary syndrome.
    Diamanti-Kandarakis E; Economou F
    Ann N Y Acad Sci; 2006 Nov; 1083():54-62. PubMed ID: 17148733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Polycystic ovarian syndrome is a health risk].
    Hippeläinen M
    Duodecim; 2002; 118(10):981-3. PubMed ID: 12238006
    [No Abstract]   [Full Text] [Related]  

  • 23. Obesity and polycystic ovary syndrome.
    Barber TM; McCarthy MI; Wass JA; Franks S
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):137-45. PubMed ID: 16886951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanisms of insulin resistance and associated diseases.
    Mlinar B; Marc J; Janez A; Pfeifer M
    Clin Chim Acta; 2007 Jan; 375(1-2):20-35. PubMed ID: 16956601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic syndrome: focus on dyslipidemia.
    Ginsberg HN; Zhang YL; Hernandez-Ono A
    Obesity (Silver Spring); 2006 Feb; 14 Suppl 1():41S-49S. PubMed ID: 16642962
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome.
    Cattrall FR; Healy DL
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):803-12. PubMed ID: 15380148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events.
    Zarich SW
    Rev Cardiovasc Med; 2005; 6(4):194-205. PubMed ID: 16379015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
    Chan JC; Tong PC; Critchley JA
    Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of appropriate patients for cardiometabolic risk management.
    Peters AL
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S9-16. PubMed ID: 17934394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycystic ovary syndrome in obese adolescents.
    Stanley T; Misra M
    Curr Opin Endocrinol Diabetes Obes; 2008 Feb; 15(1):30-6. PubMed ID: 18185060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycystic ovary syndrome, obesity and insulin resistance: the new female triad.
    Murray R
    Adv Nurse Pract; 2004 Aug; 12(8):22-35; quiz 36. PubMed ID: 15354503
    [No Abstract]   [Full Text] [Related]  

  • 34. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
    Verit FF
    Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance syndrome and polycystic ovary syndrome: implications for diagnosis and treatment.
    Tan S; Hahn S; Janssen OE
    Panminerva Med; 2005 Dec; 47(4):211-7. PubMed ID: 16489320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine abnormalities. Foreword.
    Schapiro NA
    Curr Probl Pediatr Adolesc Health Care; 2013; 43(5):103. PubMed ID: 23582591
    [No Abstract]   [Full Text] [Related]  

  • 38. Ovarian function and obesity--interrelationship, impact on women's reproductive lifespan and treatment options.
    Rachoń D; Teede H
    Mol Cell Endocrinol; 2010 Mar; 316(2):172-9. PubMed ID: 19818376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the risk for cardiovascular disease increased in all phenotypes of the polycystic ovary syndrome?
    Daskalopoulos GN; Karkanaki A; Karagiannis A; Mikhailidis DP; Athyros VG
    Angiology; 2011 May; 62(4):285-90. PubMed ID: 21474465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term risks of polycystic ovaries syndrome].
    Lefebvre P; Raingeard I; Renard E; Bringer J
    Gynecol Obstet Fertil; 2004 Mar; 32(3):193-8. PubMed ID: 15123116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.